投稿信息
投稿信息
审稿周期
投稿命中率
审稿费用
暂无数据
版面费用
暂无数据
中国人发表比例
2023年中国人文章占该期刊总数量暂无数据 (2022年为100.00%)
自引率
0.8 %
年文章数
1144
作者需知
暂无数据
NCBI查询
期刊简介
稿件收录要求
稿件收录要求
Published by Informa Pharmaceutical Science (formerly Ashley Publications).
ISSN: 1472-8222.
Expert Opinion on Therapeutic Targets is the premier journal dedicated to in-depth reports and reviews of the latest developments in the field of drug target discovery and validation. Expert Opinion on Therapeutic Targets is a peer-reviewed journal providing evaluated and expert reviews of recent research identifying novel molecular drug targets. The journal provides an essential link between basic research on biological pathways and interactions, and the development of the drugs of tomorrow. It is distinguished from other publications by its high-quality authorship and expertly drafted articles which are structured to incorporate the author's own expertise on the subject. The audience consists of scientists, managers and decision makers in the pharmaceutical industry, and others closely involved in R&D. Subscribers include most of the major pharmaceutical companies in the USA, Europe and Japan, as well as many biotechnology companies.
Expert Opinion on Therapeutic Targets is the premier journal dedicated to in-depth reports and reviews of the latest developments in the field of drug target discovery and validation. Expert Opinion on Therapeutic Targets is a peer-reviewed journal providing evaluated and expert reviews of recent research identifying novel molecular drug targets. The journal provides an essential link between basic research on biological pathways and interactions, and the development of the drugs of tomorrow. It is distinguished from other publications by its high-quality authorship and expertly drafted articles which are structured to incorporate the author's own expertise on the subject. The audience consists of scientists, managers and decision makers in the pharmaceutical industry, and others closely involved in R&D. Subscribers include most of the major pharmaceutical companies in the USA, Europe and Japan, as well as many biotechnology companies.
